Panel, Conference Presentation
Bending the Cost Curve: Understanding the GLP-1 Era | Global Conference 2025
- GLP-1 drugs represent a historically unique medical advancement capable of significantly reducing obesity, cardiovascular issues, osteoporosis, and Type 2 diabetes, offering potential long-term societal benefits including increased productivity and longevity.
- Data from Aon's database of 50 million people, analyzing 139,000 adherent users over two years, shows a 44% improvement in cardiovascular health and osteoporosis rates, with total healthcare costs dropping by approximately 7% net of drug costs by the second year.
- The immediate financial reality involves high upfront costs, with list prices historically around $1,300/month, though rebates have recently lowered the effective cost for some to roughly $550/month (approx. $6,600/year).
- Adherence is the critical variable for success; globally, the average user stays on the medication for only 90 days, with 50% discontinuing use, primarily due to cost, side effects, and lack of accessibility.
- A pilot program in the UK using telehealth, AI-driven remote monitoring, and mandatory initial blood screening achieved a 98% retention rate among 25,000 participants, contrasting sharply with the general 50% dropout rate.
- Michael Farrow identifies obesity discrimination and stigma as the primary barrier to adoption, noting that while 50% of the population views obesity as a disease, the other half attributes it to a lack of willpower, hindering reimbursement and access.
- Employers face a "tsunami" of demand as employees seek these drugs; failure to provide covered access could lead to workers resorting to unregulated black market compounds (potentially containing fentanyl) or switching to employers offering robust benefits.
- Counterfeit GLP-1 drugs are a growing risk, with prices ranging from $200–$300/month on the black market, prompting stricter FDA regulations and highlighting the need for employer-managed programs to ensure safety and supply chain integrity.
- The cost of managing GLP-1 therapy has been reduced from over 100 clinical hours per year to approximately 12 hours per year through the implementation of AI, telehealth, and asynchronous care models.
- Simon Johnson notes that the long-term cost curve is expected to bend as competition increases, potentially leading to oral formulations and generic pricing similar to statins, though specific timelines for such reductions remain uncertain.
- A significant fiscal challenge exists regarding who pays for the drug versus who reaps the savings; employers may bear immediate costs while governments save on future Medicaid/Medicare claims, or a worker's health improvements may benefit a future employer.
- State Medicaid programs are being encouraged to adopt these drugs to keep patients healthier longer, potentially delaying their transition to Medicare and reducing overall state expenditures, though political and budgetary hurdles remain.
- Aon has committed to providing GLP-1 coverage to its 66,000 US employees and their families, partnering with eMed to manage adherence and navigation, viewing the investment as essential for workforce retention and productivity.
- The conversation highlights that 40% of the US population suffers from obesity, which is a comorbidity risk factor for over 60 other conditions, justifying a holistic employer approach rather than relying solely on lifestyle interventions which have historically failed at scale.
- Dr. Oz emphasizes the need for government and corporate cooperation to create accountable programs that prevent fraud, ensure consistent access, and manage the complex titration requirements necessary for life-long treatment.
- Future innovations discussed include the potential for higher-dose oral versions of GLP-1s (specifically from Novo Nordisk and Eli Lilly) to compete more effectively and further reduce the barrier to entry.
- The panel concludes that while the ROI is proven for adherent users, the full realization of cost savings and productivity gains depends on overcoming systemic stigma, standardizing care access, and aligning payer incentives across employers, insurers, and government entities.